The Experts below are selected from a list of 189474 Experts worldwide ranked by ideXlab platform
Stefania Mondello - One of the best experts on this subject based on the ideXlab platform.
-
insight into pre clinical models of traumatic brain injury using circulating brain damage biomarkers Operation brain trauma therapy
Journal of Neurotrauma, 2016Co-Authors: Stefania Mondello, Deborah A Shear, Helen M Bramlett, Edward C Dixon, Kara Schmid, Dalton W Dietrich, Kevin K W Wang, Ronald L Hayes, Olena Glushakova, Michael CataniaAbstract:Abstract Operation Brain Trauma Therapy (OBTT) is a multicenter pre-clinical drug screening consortium testing promising therapies for traumatic brain injury (TBI) in three well-established models of TBI in rats—namely, parasagittal fluid percussion injury (FPI), controlled cortical impact (CCI), and penetrating ballistic-like brain injury (PBBI). This article presents unique characterization of these models using histological and behavioral outcomes and novel candidate biomarkers from the first three treatment trials of OBTT. Adult rats underwent CCI, FPI, or PBBI and were treated with vehicle (VEH). Shams underwent all manipulations except trauma. The glial marker glial fibrillary acidic protein (GFAP) and the neuronal marker ubiquitin C-terminal hydrolase (UCH-L1) were measured by enzyme-linked immunosorbent assay in blood at 4 and 24 h, and their delta 24–4 h was calculated for each marker. Comparing sham groups across experiments, no differences were found in the same model. Similarly, comparing TBI ...
-
synthesis of findings current investigations and future directions Operation brain trauma therapy
Journal of Neurotrauma, 2016Co-Authors: Patrick M Kochanek, Stefania Mondello, Deborah A Shear, Helen M Bramlett, Edward C Dixon, Dalton W Dietrich, Kevin K W Wang, Ronald L Hayes, Samuel M Poloyac, Philip E EmpeyAbstract:Abstract Operation Brain Trauma Therapy (OBTT) is a fully Operational, rigorous, and productive multicenter, pre-clinical drug and circulating biomarker screening consortium for the field of traumatic brain injury (TBI). In this article, we synthesize the findings from the first five therapies tested by OBTT and discuss both the current work that is ongoing and potential future directions. Based on the results generated from the first five therapies tested within the exacting approach used by OBTT, four (nicotinamide, erythropoietin, cyclosporine A, and simvastatin) performed below or well below what was expected based on the published literature. OBTT has identified, however, the early post-TBI administration of levetiracetam as a promising agent and has advanced it to a gyrencephalic large animal model—fluid percussion injury in micropigs. The sixth and seventh therapies have just completed testing (glibenclamide and Kollidon VA 64), and an eighth drug (AER 271) is in testing. Incorporation of circulati...
Philip E Empey - One of the best experts on this subject based on the ideXlab platform.
-
synthesis of findings current investigations and future directions Operation brain trauma therapy
Journal of Neurotrauma, 2016Co-Authors: Patrick M Kochanek, Stefania Mondello, Deborah A Shear, Helen M Bramlett, Edward C Dixon, Dalton W Dietrich, Kevin K W Wang, Ronald L Hayes, Samuel M Poloyac, Philip E EmpeyAbstract:Abstract Operation Brain Trauma Therapy (OBTT) is a fully Operational, rigorous, and productive multicenter, pre-clinical drug and circulating biomarker screening consortium for the field of traumatic brain injury (TBI). In this article, we synthesize the findings from the first five therapies tested by OBTT and discuss both the current work that is ongoing and potential future directions. Based on the results generated from the first five therapies tested within the exacting approach used by OBTT, four (nicotinamide, erythropoietin, cyclosporine A, and simvastatin) performed below or well below what was expected based on the published literature. OBTT has identified, however, the early post-TBI administration of levetiracetam as a promising agent and has advanced it to a gyrencephalic large animal model—fluid percussion injury in micropigs. The sixth and seventh therapies have just completed testing (glibenclamide and Kollidon VA 64), and an eighth drug (AER 271) is in testing. Incorporation of circulati...
Edward C Dixon - One of the best experts on this subject based on the ideXlab platform.
-
insight into pre clinical models of traumatic brain injury using circulating brain damage biomarkers Operation brain trauma therapy
Journal of Neurotrauma, 2016Co-Authors: Stefania Mondello, Deborah A Shear, Helen M Bramlett, Edward C Dixon, Kara Schmid, Dalton W Dietrich, Kevin K W Wang, Ronald L Hayes, Olena Glushakova, Michael CataniaAbstract:Abstract Operation Brain Trauma Therapy (OBTT) is a multicenter pre-clinical drug screening consortium testing promising therapies for traumatic brain injury (TBI) in three well-established models of TBI in rats—namely, parasagittal fluid percussion injury (FPI), controlled cortical impact (CCI), and penetrating ballistic-like brain injury (PBBI). This article presents unique characterization of these models using histological and behavioral outcomes and novel candidate biomarkers from the first three treatment trials of OBTT. Adult rats underwent CCI, FPI, or PBBI and were treated with vehicle (VEH). Shams underwent all manipulations except trauma. The glial marker glial fibrillary acidic protein (GFAP) and the neuronal marker ubiquitin C-terminal hydrolase (UCH-L1) were measured by enzyme-linked immunosorbent assay in blood at 4 and 24 h, and their delta 24–4 h was calculated for each marker. Comparing sham groups across experiments, no differences were found in the same model. Similarly, comparing TBI ...
-
synthesis of findings current investigations and future directions Operation brain trauma therapy
Journal of Neurotrauma, 2016Co-Authors: Patrick M Kochanek, Stefania Mondello, Deborah A Shear, Helen M Bramlett, Edward C Dixon, Dalton W Dietrich, Kevin K W Wang, Ronald L Hayes, Samuel M Poloyac, Philip E EmpeyAbstract:Abstract Operation Brain Trauma Therapy (OBTT) is a fully Operational, rigorous, and productive multicenter, pre-clinical drug and circulating biomarker screening consortium for the field of traumatic brain injury (TBI). In this article, we synthesize the findings from the first five therapies tested by OBTT and discuss both the current work that is ongoing and potential future directions. Based on the results generated from the first five therapies tested within the exacting approach used by OBTT, four (nicotinamide, erythropoietin, cyclosporine A, and simvastatin) performed below or well below what was expected based on the published literature. OBTT has identified, however, the early post-TBI administration of levetiracetam as a promising agent and has advanced it to a gyrencephalic large animal model—fluid percussion injury in micropigs. The sixth and seventh therapies have just completed testing (glibenclamide and Kollidon VA 64), and an eighth drug (AER 271) is in testing. Incorporation of circulati...
Helen M Bramlett - One of the best experts on this subject based on the ideXlab platform.
-
insight into pre clinical models of traumatic brain injury using circulating brain damage biomarkers Operation brain trauma therapy
Journal of Neurotrauma, 2016Co-Authors: Stefania Mondello, Deborah A Shear, Helen M Bramlett, Edward C Dixon, Kara Schmid, Dalton W Dietrich, Kevin K W Wang, Ronald L Hayes, Olena Glushakova, Michael CataniaAbstract:Abstract Operation Brain Trauma Therapy (OBTT) is a multicenter pre-clinical drug screening consortium testing promising therapies for traumatic brain injury (TBI) in three well-established models of TBI in rats—namely, parasagittal fluid percussion injury (FPI), controlled cortical impact (CCI), and penetrating ballistic-like brain injury (PBBI). This article presents unique characterization of these models using histological and behavioral outcomes and novel candidate biomarkers from the first three treatment trials of OBTT. Adult rats underwent CCI, FPI, or PBBI and were treated with vehicle (VEH). Shams underwent all manipulations except trauma. The glial marker glial fibrillary acidic protein (GFAP) and the neuronal marker ubiquitin C-terminal hydrolase (UCH-L1) were measured by enzyme-linked immunosorbent assay in blood at 4 and 24 h, and their delta 24–4 h was calculated for each marker. Comparing sham groups across experiments, no differences were found in the same model. Similarly, comparing TBI ...
-
synthesis of findings current investigations and future directions Operation brain trauma therapy
Journal of Neurotrauma, 2016Co-Authors: Patrick M Kochanek, Stefania Mondello, Deborah A Shear, Helen M Bramlett, Edward C Dixon, Dalton W Dietrich, Kevin K W Wang, Ronald L Hayes, Samuel M Poloyac, Philip E EmpeyAbstract:Abstract Operation Brain Trauma Therapy (OBTT) is a fully Operational, rigorous, and productive multicenter, pre-clinical drug and circulating biomarker screening consortium for the field of traumatic brain injury (TBI). In this article, we synthesize the findings from the first five therapies tested by OBTT and discuss both the current work that is ongoing and potential future directions. Based on the results generated from the first five therapies tested within the exacting approach used by OBTT, four (nicotinamide, erythropoietin, cyclosporine A, and simvastatin) performed below or well below what was expected based on the published literature. OBTT has identified, however, the early post-TBI administration of levetiracetam as a promising agent and has advanced it to a gyrencephalic large animal model—fluid percussion injury in micropigs. The sixth and seventh therapies have just completed testing (glibenclamide and Kollidon VA 64), and an eighth drug (AER 271) is in testing. Incorporation of circulati...
Ronald L Hayes - One of the best experts on this subject based on the ideXlab platform.
-
insight into pre clinical models of traumatic brain injury using circulating brain damage biomarkers Operation brain trauma therapy
Journal of Neurotrauma, 2016Co-Authors: Stefania Mondello, Deborah A Shear, Helen M Bramlett, Edward C Dixon, Kara Schmid, Dalton W Dietrich, Kevin K W Wang, Ronald L Hayes, Olena Glushakova, Michael CataniaAbstract:Abstract Operation Brain Trauma Therapy (OBTT) is a multicenter pre-clinical drug screening consortium testing promising therapies for traumatic brain injury (TBI) in three well-established models of TBI in rats—namely, parasagittal fluid percussion injury (FPI), controlled cortical impact (CCI), and penetrating ballistic-like brain injury (PBBI). This article presents unique characterization of these models using histological and behavioral outcomes and novel candidate biomarkers from the first three treatment trials of OBTT. Adult rats underwent CCI, FPI, or PBBI and were treated with vehicle (VEH). Shams underwent all manipulations except trauma. The glial marker glial fibrillary acidic protein (GFAP) and the neuronal marker ubiquitin C-terminal hydrolase (UCH-L1) were measured by enzyme-linked immunosorbent assay in blood at 4 and 24 h, and their delta 24–4 h was calculated for each marker. Comparing sham groups across experiments, no differences were found in the same model. Similarly, comparing TBI ...
-
synthesis of findings current investigations and future directions Operation brain trauma therapy
Journal of Neurotrauma, 2016Co-Authors: Patrick M Kochanek, Stefania Mondello, Deborah A Shear, Helen M Bramlett, Edward C Dixon, Dalton W Dietrich, Kevin K W Wang, Ronald L Hayes, Samuel M Poloyac, Philip E EmpeyAbstract:Abstract Operation Brain Trauma Therapy (OBTT) is a fully Operational, rigorous, and productive multicenter, pre-clinical drug and circulating biomarker screening consortium for the field of traumatic brain injury (TBI). In this article, we synthesize the findings from the first five therapies tested by OBTT and discuss both the current work that is ongoing and potential future directions. Based on the results generated from the first five therapies tested within the exacting approach used by OBTT, four (nicotinamide, erythropoietin, cyclosporine A, and simvastatin) performed below or well below what was expected based on the published literature. OBTT has identified, however, the early post-TBI administration of levetiracetam as a promising agent and has advanced it to a gyrencephalic large animal model—fluid percussion injury in micropigs. The sixth and seventh therapies have just completed testing (glibenclamide and Kollidon VA 64), and an eighth drug (AER 271) is in testing. Incorporation of circulati...
